Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1800727 | 0.77 | CCNT1 (0.30) | CCNT1CDK9 | |
| SCHEMBL7925552 | 0.77 | MAPT (0.35) | CCNT1CDK9 | |
| SCHEMBL17869465 | 0.77 | CHRNB2 (0.31) | CCNT1CDK9 | |
| SCHEMBL12265082 | 0.77 | SSTR4 (0.32) | CCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL8156603 | 0.76 | — | — | |
| SCHEMBL4206342 | 0.73 | DRD2 (0.33) | CCNT1CDK9 | |
| SCHEMBL5151795 | 0.73 | CYP11B1 (0.38) | — | |
| SCHEMBL18013173 | 0.73 | MAPT (0.36) | CCNT1CDK9 | |
| SCHEMBL9869341 | 0.72 | POLB (0.38) | CCNT1CDK9 | |
| SCHEMBL25274344 | 0.70 | CCNT1 (0.32) | CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067655-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20220340592-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2022-10-27 | — | — | US | disclosed |
| US-11352369-B2 | Pyridine and pyrimidine derivatives | ASTRAZENECA AB (SE) | 2022-06-07 | — | — | US | disclosed |
| US-11352369-B2 | Pyridine and pyrimidine derivatives | ASTRAZENECA AB (SE) | 2022-06-07 | — | — | US | disclosed |
| EP-3539961-B1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | ASTRAZENECA AB (SE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3539961-B1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | ASTRAZENECA AB (SE) | 2021-10-06 | — | — | EP | disclosed |
| US-20210171541-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2021-06-10 | — | — | US | disclosed |
| US-20210171541-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2021-06-10 | — | — | US | disclosed |
| CN-107873028-B | Polycyclic amide derivatives useful as CDK9 inhibitors | 阿斯利康(瑞典)有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-10717746-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-07-21 | — | — | US | disclosed |
| EP-3539961-A1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | Astrazeneca AB (SE) | 2019-09-18 | — | — | EP | disclosed |
| EP-3539961-A1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | Astrazeneca AB (SE) | 2019-09-18 | — | — | EP | disclosed |
| EP-3313838-B1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | ASTRAZENECA AB (SE) | 2019-04-03 | — | — | EP | disclosed |
| EP-3313838-B1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | ASTRAZENECA AB (SE) | 2019-04-03 | — | — | EP | disclosed |
| US-20180093998-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-04-05 | — | — | US | disclosed |
| US-20180093998-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-04-05 | — | — | US | disclosed |
| US-9845331-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2017-12-19 | — | — | US | disclosed |
| US-9845331-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2017-12-19 | — | — | US | disclosed |
| WO-2017001354-A1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | ASTRAZENECA AB (SE) | 2017-01-05 | — | — | WO | disclosed |
| US-20160376287-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340592-A1 | CHEMICAL COMPOUNDS | CDK9, BCL9, BCL9L | CCNT1 49/4885CDK9 1/4885 |
| US-20240067655-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, NUAK1, NUAK2 | CCNT1 3067/4885CDK9 289/4885 |
| US-20210171541-A1 | CHEMICAL COMPOUNDS | CDK9, BCL9, BCL9L | CCNT1 49/4885CDK9 1/4885 |
| US-20160376287-A1 | Chemical Compounds | CDK9, BCL9, BCL9L | CCNT1 49/4885CDK9 1/4885 |
| US-10717746-B2 | Chemical compounds | CDK9, BCL9, BCL9L | CCNT1 49/4885CDK9 1/4885 |
| US-20180093998-A1 | CHEMICAL COMPOUNDS | CDK9, BCL9, BCL9L | CCNT1 49/4885CDK9 1/4885 |
| US-11352369-B2 | Pyridine and pyrimidine derivatives | CDK9, BCL9, CDK19 | CCNT1 46/4885CDK9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.